Am I Eligible for Wegovy Tablets Privately in the UK?

Written by the ClariDay clinical team. Medically reviewed by Ali Salih, GPhC-registered Pharmacist Independent Prescriber (/author/ali-salih).Reviewed 21 July 2026. Next review 21 August 2026 (eligibility and availability content is checked monthly).Every clinical and regulatory claim on this page is sourced to a primary UK reference: the MHRA, the tablet's Summary of Product Characteristics, and NICE. Sources are listed at the end.

Privately, you can usually be prescribed Wegovy tablets if you are an adult with a BMI of 30 or above, or 27 to just under 30 with a weight-related condition such as high blood pressure. That is the licensed use a private prescriber works to, and they still assess you first, so the BMI figure only starts the decision.

The Wegovy tablet (oral semaglutide) was licensed by the MHRA on 11 June 2026 and began reaching UK pharmacies from early July 2026 [7]. Because it is a prescription-only medicine, nobody can simply buy it. So the real question, "am I eligible for Wegovy tablets privately?", comes down to the medicine's licence and a prescriber's judgement, and the private rules are not the same as the NHS ones. This page explains where you are likely to stand before you book, and why the answer is rarely a single number.

What are the eligibility criteria for Wegovy tablets privately?

You can be considered for Wegovy tablets privately if you are an adult with a body mass index (BMI) of 30 or more. You can also be considered with a BMI between 27 and 30 if you have a weight-related health condition. BMI is a simple height-to-weight measure, and a private clinic will usually work it out for you.

These thresholds come straight from the medicine's licence. The Summary of Product Characteristics, the official rulebook for how the tablet may be used, sets it out for "weight management ... in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity), or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity" [1]. A comorbidity simply means another health problem linked to your weight. The licence also treats the tablet as something you add to healthier eating and more activity, not a replacement for them.

If your BMI is between 27 and 30, you need one of those weight-related conditions to qualify. The ones that count are the health problems that carrying extra weight tends to cause. In practice that means things like high blood pressure, high cholesterol, type 2 diabetes or pre-diabetes, sleep apnoea (breathing that stops and starts during sleep), or heart disease [2]. If your BMI is 30 or above, you do not need any other condition to meet the threshold.

One boundary is firm. The tablet is licensed for adults only. Its safety and effectiveness in anyone under 18 "have not been established," so a private prescriber will not supply it to a child or young person [1].

Am I eligible for Wegovy tablets if my BMI is over 30?

Meeting the BMI threshold means you can be considered, not that you will be prescribed. The figure opens the assessment; it does not complete it.

BMI is a useful check, but a rough one. NICE, the body that guides UK care, says BMI should be read "with caution because it is not a direct measure of central adiposity," in other words it does not measure fat directly, and that it can mislead in people with a lot of muscle or aged 65 and over [3]. Someone very muscular can be above 30 without carrying too much fat, which is part of why a person, not a calculator, makes the decision.

There is also an adjustment many people never hear about, and it lowers the bar rather than raising it. People from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds tend to face weight-related health risk at a lower BMI. So NICE sets lower thresholds for them: overweight from a BMI of 23, and obesity from 27.5 [3]. If your background is one of these, you may qualify at a BMI where someone else would not, so it is worth raising at your assessment.

Who cannot take Wegovy tablets?

Some people should not take the tablet at all, and a prescriber screens for this before anything is supplied. The clearest situations are pregnancy and breastfeeding. Semaglutide "should not be used during pregnancy," should be stopped "at least 2 months before" trying to conceive, and "should not be used during breast-feeding" [1]. If you are pregnant, planning a pregnancy, or breastfeeding, this is not the right time for the medicine.

A known allergy to semaglutide or to anything in the tablet is the other clear reason not to take it [1]. Beyond that, some medical histories call for caution rather than an automatic no. The tablet has not been tested in people who have had pancreatitis (inflammation of the pancreas), so it is used carefully there. It is also not recommended if you have severe kidney or liver problems [1]. A personal or family history of a rare thyroid cancer, or of a linked condition called MEN 2, is another point a prescriber weighs carefully, as with all medicines of this type. And if you already take insulin or a sulfonylurea tablet for diabetes, your prescriber may lower those doses, because semaglutide can raise the chance of low blood sugar when they are combined [1].

None of these are box-ticking. They are the reasons the assessment exists, and they are why your medical history matters as much as your BMI.

Is the private route the same as the NHS?

No, and this is where most confusion sits. The private route and the NHS route are governed by two different systems, and the private bar is the lower of the two.

Privately, eligibility follows the licence described above. A prescriber checks you against the licensed use and their own judgement, working to the professional standards set by the General Pharmaceutical Council, the UK regulator for pharmacists. On the NHS, access is decided by NICE, which sets stricter rules to manage cost. For the semaglutide injection, NICE only recommends treatment inside a specialist weight-management service, for up to two years, and usually from a BMI of 35 (or 30 to 34.9 if you meet referral rules) with a weight-related condition [4]. The lower thresholds for the ethnic backgrounds above apply here too, cut by 2.5 [4]. So you can fall short of the NHS rules and still meet the lower bar a private clinic works to.

For the tablet specifically, the NHS position is simpler: it is not funded. The MHRA was explicit that "whilst this tablet is approved for use in the UK, it is not available currently via the NHS" [5]. It is sometimes said that this is only a matter of waiting for NICE, but the dedicated NICE appraisal of oral semaglutide for weight management was in fact discontinued in May 2025, after the manufacturer told NICE it "will not provide an evidence submission" [6]. In other words, there is no live NHS appraisal for the tablet to clear at present, so for now the tablet is a private option; we cover this in full on our page on whether Wegovy tablets are available on the NHS. If cost is your main question, our guide to their cost and access sets out what private treatment involves.

What happens at a private eligibility assessment?

A private assessment is a proper clinical consultation, not a form. It exists to confirm two things: that the medicine is licensed for someone in your situation, and that it is safe for you specifically.

A prescriber will usually check your height and weight to work out your BMI, ask about the conditions that matter for the 27 to 30 route, and go through your medical history, current medicines and any allergies. They will run through the situations above, such as pregnancy plans, past pancreatitis, kidney and liver health, and diabetes treatment, so nothing is missed. Because the tablet has a strict daily routine, taken on an empty stomach with only a sip of water, they will also talk through whether that fits your day. If treatment starts, it is reviewed over time rather than handed over once, so your progress and any side effects can be checked and the plan adjusted.

If you buy online, the same standards apply. A legitimate UK service is registered with the General Pharmaceutical Council and should assess you before prescribing; a site that will sell you the tablet with no real assessment is one to avoid.

Frequently asked questions

What BMI do you need for Wegovy tablets? A BMI of 30 or above, or 27 to just under 30 with at least one weight-related health condition, is the licensed threshold a private prescriber works to [1]. Lower thresholds apply for several ethnic backgrounds [3].

Can I get Wegovy tablets on the NHS? Not at present. The MHRA confirmed the tablet is "not available currently via the NHS" [5], and the NICE appraisal that would have assessed NHS funding was discontinued in 2025 [6]. It is available privately.

Do I need a weight-related condition to qualify? Only if your BMI is between 27 and 30. At a BMI of 30 or above, the licensed threshold is met without one [1].

Can I take Wegovy tablets if I am pregnant or breastfeeding? No, semaglutide should not be used in pregnancy or while breastfeeding, and it should be stopped at least two months before trying to conceive [1].

Is there an age limit? Yes, the tablet is licensed for adults only, and its safety in under-18s has not been established [1].

Will a high BMI alone get me a prescription? Not on its own. It means you can be assessed. A prescriber still checks your history and the situations where the medicine is unsuitable before prescribing [1][3].

If you are considering treatment

If you think you may be eligible, the practical next step is to check your BMI with our BMI calculator and then book a consultation with a prescriber who can confirm whether the Wegovy tablet suits you. If you are still getting your bearings, our guide to what the Wegovy pill is and how it works explains the basics. And if you are weighing the tablet against other treatments, Wegovy tablets vs Rybelsus compares the two oral options, while our Mounjaro guide covers the main weekly injection.

This article is general information, not medical advice, and is not a substitute for a consultation with a qualified prescriber.

---

References

1. Novo Nordisk Ltd. (2026). Wegovy 25 mg tablets: Summary of Product Characteristics (SmPC). Electronic medicines compendium (emc). Retrieved 21 July 2026, from https://www.medicines.org.uk/emc/product/102347/smpc

2. Novo Nordisk Ltd. (2026). Wegovy 2.4 mg solution for injection: Summary of Product Characteristics (SmPC), section 4.1 (weight-related comorbidities). Electronic medicines compendium (emc). Retrieved 21 July 2026, from https://www.medicines.org.uk/emc/product/13803/smpc

3. National Institute for Health and Care Excellence. (2025, updated 2026). Overweight and obesity management (NG246): Identifying and assessing overweight, obesity and central adiposity (recommendations 1.9.7, 1.9.11, 1.9.12, 1.9.13). Retrieved 21 July 2026, from https://www.nice.org.uk/guidance/ng246/chapter/Identifying-and-assessing-overweight-obesity-and-central-adiposity

4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity (TA875), recommendation 1.1. Retrieved 21 July 2026, from https://www.nice.org.uk/guidance/ta875/chapter/1-Recommendations

5. Medicines and Healthcare products Regulatory Agency. (2026, June 11). First GLP-1 tablet for weight loss approved in the UK. GOV.UK. Retrieved 21 July 2026, from https://www.gov.uk/government/news/first-glp-1-tablet-for-weight-loss-approved-in-the-uk

6. National Institute for Health and Care Excellence. (2025). Oral semaglutide for managing overweight and obesity [GID-TA11149 / ID6188]: appraisal discontinued 12 May 2025. Retrieved 21 July 2026, from https://www.nice.org.uk/guidance/awaiting-development/GID-TA11149

7. Pharmacy Magazine. (2026, July 6). Pharmacies placing "large orders" with wholesalers as Wegovy tablets launch in UK (market/availability report; initial 1.5 mg and 4 mg strengths available, higher strengths following). Retrieved 21 July 2026, from https://www.pharmacymagazine.co.uk/business-news/pharmacies-placing-large-orders-with-wholesalers-as-wegovy-tablets-launch-in-uk

Further reading (effectiveness): Wharton, S., Lingvay, I., Bogdanski, P., et al. (2025). Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). New England Journal of Medicine, 393(11), 1077-1087. https://doi.org/10.1056/NEJMoa2500969

---